Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals board meetings
104 filed, newest first. Page 2 of 3.
Nov 2017
2 Nov · Board meeting
Oct 2017
Jul 2017
May 2017
11 May · Board meeting
Jan 2017
Oct 2016
Jul 2016
Apr 2016
Jan 2016
Oct 2015
29 Oct · Board meeting
Jul 2015
May 2015
Apr 2015
17 Apr · Board meeting
Jan 2015
30 Jan · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2014.
Oct 2014
17 Oct · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half year ended September 30, 2014. Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from October 17, 2014 to October 31, 2014 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter/Half year ended September 30, 2014.
Jul 2014
24 Jul · Board meeting
Board of Directors of the Company at its Meeting held on July 24, 2014 allotted 24,100 equity shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Apr 2014
Jan 2014
14 Jan · Board meeting
To consider and approve the Company's Un-audited Financial Statements for the Third Quarter ended December 31, 2013.
Oct 2013
21 Oct · Board meeting
To consider and approve the Company's un-audited Financial Statements for the Second Quarter/Half year ended September 30, 2013.
Jul 2013
19 Jul · Board meeting
To consider and approve the Company's Un-audited Financial Statements for the First Quarter ended 30th June, 2013.
Apr 2013
26 Apr · Board meeting
1. To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2013. 2. To Consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2013.
Jan 2013
18 Jan · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2012.
Oct 2012
19 Oct · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Second Quarter/ Half year ended September 30, 2012.
Jul 2012
23 Jul · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the quarter ended June 30, 2012.
Apr 2012
27 Apr · Board meeting
(1) To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2012; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2012.
Jan 2012
19 Jan · Board meeting
To consider and approve the Un-Audited Financial Results for the third quarter ended December 31, 2011.
Nov 2011
11 Nov · Board meeting
Mr. R. V. Desai, CFO has been appointed as Executive Director at the Board Meeting held on November 09, 2011.
Oct 2011
25 Oct · Board meeting
To consider the Un-Audited Financial Results for the Q2 / Half year ended September 30, 2011.
Jul 2011
15 Jul · Board meeting
To consider and approve the Un-Audited Financial Results for the First Quarter ended June 30, 2011.
May 2011
2 May · Board meeting
(1) To consider and approve the Company's Audited Financial Statements for the Year ended March 31, 2011; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2011.
Jan 2011
24 Jan · Board meeting
To consider the Un-Audited Financial Results for the Third Quarter ended December 31, 2010.
Oct 2010
18 Oct · Board meeting
To consider and approve the Un-Audited Financial Results for the Second Quarter/Half year ended September 30, 2010.
Jul 2010
16 Jul · Board meeting
To consider and approve the Un-audited Financial Results for the First Quarter ended June 30, 2010.
May 2010
17 May · Board meeting
Inter alia, to consider the following : (1) To consider and approve the Company's audited financial statements for the 4th quarter and year ended March 31, 2010; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2010.
Jan 2010
21 Jan · Board meeting
To consider and approve the Un-Audited Financial Results for the Third Quarter ended December 31, 2009.
Oct 2009
20 Oct · Board meeting
To consider and approve the Un-Audited Financial Results for the Second Quarter / Half Year ended September 30, 2009.
Jul 2009
17 Jul · Board meeting
To consider and approve the Un-Audited Financial Results for the First Quarter ended June 30, 2009.
Jun 2009
18 Jun · Board meeting
1) To consider and approve the Company's audited financial statements for the year ended March 31, 2009. 2) To consider declaration of dividend on Equity Shares for the year ended March 31, 2009.
Apr 2009
17 Apr · Board meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its Meeting held on April 17, 2009 allotted 7,000 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Jan 2009
9 Jan · Board meeting
Meeting on 27 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
20 Oct · Board meeting
To consider and approve the Un-audited Financial results for the second quarter/ half year ended September 30, 2008.
Jul 2008
18 Jul · Board meeting
Meeting on 28 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
19 Apr · Board meeting
To consider and approve the Audited Financial Results for the 4th Quarter/Year ended March 31, 2008.
Jan 2008
2 Jan · Board meeting
Meeting on 21 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
23 Oct · Board meeting
To approve the Un-Audited Financial Results for the 2nd Quarter/ Half ended September 30, 2007 and inter alia may also consider payment of Interim Dividend on Equity Shares of the Company for the financial year 2007-2008.